Ravi K Amaravadi, MD
Ravi K Amaravadi, MD
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Hematology-Oncology Division
University of Pennsylvania
16 Penn Tower
3400 Spruce St.
Philadelphia, PA 19104
University of Pennsylvania
16 Penn Tower
3400 Spruce St.
Philadelphia, PA 19104
Office: 215-662-7402
Fax: 215-349-8550
Fax: 215-349-8550
Publications
Education:
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent linkBA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Description of Research Expertise
Autophagy, Mechanisms of Cell Death, Developmental TherapeuticsDescription of Clinical Expertise
Phase I and Phase II Clinical TrialsMelanoma
Selected Publications
Trunzer K, Pavlick AC, Schuchter LM, Gonzalez R, McArthur GA, Hutson TE, Moschoss SJ, Flaherty KT,Kim KB, Weber JS, Hersey P, Kefford R, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo R, Koehler A, Kockx M,Spleiss O, Schell-Steven A, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A : Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients with Metastatic Melanoma. Journal of Clinical Oncology 2013.Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M: Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. Journal of the American Academy of Dermatology 67(6): 1265-72, Dec 2012 Notes: Epub 2012 May 18.
McArthur GA, Puzanov I, Amaravadi RK, Ribas A, Chapman P, Kim KB, Sosman J, Lee R, Nolop K, Flaherty KT, Callahan J; Hicks RJ: Marked, homogeneous and early FDG-PET responses to vemurafenib in BRAF-mutant advanced melanoma. Journal of Clinical Oncology 30(14): 1628-34, May 2012.
McAfee QM, Zhang Z, Samanta A, Levi S, Ma XH, Piao S, Lynch J, Sepulveda AR, Davis LE, Winkler J, Amaravadi RK: The autophagy inhibitor Lys05 has single agent antitumor activity reproduces the intestinal phenotype of a genetic autophagy deficiency. Proceedings of the National Academy of Sciences May 2012.
Sosman, Jeffrey A. Kim, Kevin B. Schuchter, Lynn. Gonzalez, Rene. Pavlick, Anna C. Weber, Jeffrey S. McArthur, Grant A. Hutson, Thomas E. Moschos, Stergios J. Flaherty, Keith T. Hersey, Peter. Kefford, Richard. Lawrence, Donald. Puzanov, Igor. Lewis, Karl D. Amaravadi, Ravi K. Chmielowski, Bartosz. Lawrence, H Jeffrey. Shyr, Yu. Ye, Fei. Li, Jiang. Nolop, Keith B. Lee, Richard J. Joe, Andrew K. Ribas, Antoni.: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine 366(8): 707-14, Feb 23 2012.
Lazova R, Camp RL, Klump V, Siddiqui S, Amaravadi R, Pawelek JM: Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis and poor outcome. Clinical Cancer Research Nov 2011.
Ma Xiao-Hong, Piao Shengfu, Wang Dan, McAfee Quentin W, Nathanson Katherine L, Lum Julian J, Li Lin Z, Amaravadi Ravi K: Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clinical Cancer Research 17(10): 3478-89, May 2011.
Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O’Dwyer PJ, Flaherty KT: Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clinical Cancer Research 15(24): 7711-7718 Dec 2009.
Amaravadi, Ravi K. Yu, Duonan. Lum, Julian J. Bui, Thi. Christophorou, Maria A. Evan, Gerard I. Thomas-Tikhonenko, Andrei. Thompson, Craig B.: Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation 117(2): 326-36, Feb 2007.
Amaravadi, Ravi K. Jacobson, Brian C. Solomon, Daniel H. Fischer, Michael A.: Acute pancreatitis associated with rofecoxib. American Journal of Gastroenterology 97(4): 1077-8, Apr 2002.